EMA Authorised: Thalidomide BMS (previously Thalidomide Celgene) (thalidomide) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorised thalidomide (Bristol-Myers Squibb) for the treatment of multiple myeloma in the EU, with Bristol-Myers Squibb Pharma EEIG as the marketing au…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalomid (thalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 21/01/2025